Biotech Values

[DewDiligence]

NVO acquires FMTX for $20.00/sh cash—a 49% premium to yesterday’s close:

https://www.globenewswire.com/news-release/2022/09/01/2508522/0/en/Novo-Nordisk-to-acquire-Forma-Therapeutics-and-expand-presence-in-sickle-cell-disease-and-rare-blood-disorders.html

The nominal deal value is $1.1B. The buyout price is exactly the same as the IPO price in 2020 (#msg-156379536), a disappointing outcome for FMTX shareholders that is surprising in view of the widespread interest in SCD (as indicated by PFE's outbidding two other companies in the acquisition of GBT).